ProCE Banner Activity

Resources to Improve the Care of Patients With NSCLC and EGFR Mutations

Slideset Download
Review this slideset from a workshop series on optimal management of EGFR-mutated advanced NSCLC, including expert insights on promising investigational agents and combination therapy.

Released: September 21, 2022

Expiration: September 20, 2023

Begin Activity

Share

Faculty

Edward B. Garon

Edward B. Garon, MD, MS

Professor
Director,
Thoracic Oncology Program
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Director, Signal Transduction and Therapeutics
Division of Hematology/Oncology
Department of Medicine
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Helena A. Yu

Helena A. Yu, MD

Associate Attending
Department of Medicine
Section Head, Molecular Targets in Lung Cancer
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Edward B. Garon, MD, MS

Professor
Director,
Thoracic Oncology Program
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Director, Signal Transduction and Therapeutics
Division of Hematology/Oncology
Department of Medicine
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Edward B. Garon, MD, MS, has disclosed that he has received funds for research support from ABL Bio, AstraZeneca, Bristol-Myers Squibb, Dynavax, EMD Serono, Genentech, Iovance, Lilly, Merck, Mirati, Neon, and Novartis and consulting fees from ABL Bio, Boehringer Ingelheim, Bristol-Myers Squibb, Dracen, Eisai, EMD Serono, GlaxoSmithKline, Lilly, Merck, Natera, Novartis, Regeneron, Sanofi, Shionogi, and Xilio.

Helena A. Yu, MD

Associate Attending
Department of Medicine
Section Head, Molecular Targets in Lung Cancer
Memorial Sloan Kettering Cancer Center
New York, New York

Helena A. Yu, MD, has disclosed that she has received funds for research support paid to her institution from AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Novartis, and Pfizer and consultant/advisor/speaker fees from AstraZeneca, Blueprint Medicine, C4 Therapeutics, Daiichi Sankyo, and Janssen Oncology.